-
公开(公告)号：US11077217B2
公开(公告)日：2021-08-03
申请号：US16215647
申请日：2018-12-11
申请人： Ming-Hsin Li , Su-Jung Chen , Ming-Wei Chen , Yuan-Ruei Huang , Shih-Ying Lee , Chun-Fang Feng , Sheng-Nan Lo , Chih-Hsien Chang
发明人： Ming-Hsin Li , Su-Jung Chen , Ming-Wei Chen , Yuan-Ruei Huang , Shih-Ying Lee , Chun-Fang Feng , Sheng-Nan Lo , Chih-Hsien Chang
摘要： The present invention provides a radioactive labeling method for neuropeptide Y (NPY) compound and a mammalian diagnostic radioactive targeting medicine with NPY peptide being modified at position 27th to 36th, and after binding with the chelating agent and labeling the radiation nucleus 66Ga67Ga68Ga177Lu or 111In to provide a radioactive targeting medicine for multi-type breast cancer diagnosis and treatment.
-
2.发明申请公开(公告)号：US20200237938A1
公开(公告)日：2020-07-30
申请号：US16215647
申请日：2018-12-11
申请人： Ming-Hsin Li , Su-Jung Chen , Ming-Wei Chen , Yuan-Ruei Huang , Shih-Ying Lee , Chun-Fang Feng , Sheng-Nan Lo , Chih-Hsien Chang
发明人： Ming-Hsin Li , Su-Jung Chen , Ming-Wei Chen , Yuan-Ruei Huang , Shih-Ying Lee , Chun-Fang Feng , Sheng-Nan Lo , Chih-Hsien Chang
摘要： The present invention provides a radioactive labeling method for neuropeptide Y (NPY) compound and a mammalian diagnostic radioactive targeting medicine with NPY peptide being modified at position 27th to 36th, and after binding with the chelating agent and labeling the radiation nucleus 66Ga, 67Ga, 68Ga, 177Lu or 111In to provide a radioactive targeting medicine for multi-type breast cancer diagnosis and treatment.
-
公开(公告)号：US11850291B2
公开(公告)日：2023-12-26
申请号：US16663387
申请日：2019-10-25
申请人： Ming-Hsin Li , Sheng-Nan Lo , Shih-Wei Lo , Shih-Ying Lee , Su-Jung Chen , Shih-Min Wang , Ming-Wei Chen , Wei-Lin Lo
发明人： Ming-Hsin Li , Sheng-Nan Lo , Shih-Wei Lo , Shih-Ying Lee , Su-Jung Chen , Shih-Min Wang , Ming-Wei Chen , Wei-Lin Lo
IPC分类号： A61K51/08
CPC分类号： A61K51/088
摘要： The invention features a novel precursor provided for radioisotope labeling with ligands for specific binding of prostate-specific membrane antigen (PSMA) for prostate cancer diagnosis and treatment, and the pharmacophore of a PSMA inhibitor composed of three molecules of glutamic acid, urea and lysine is provided with three variable linkers based on pharmacological activity of the PSMA inhibitor for labeling with radioactive nucleus Ga-67, Ga-68, In-111, Lu-177, Cu-64, or Y-90 through a chelating agent for imaging analysis of human tumor models of prostate cancer and serving as a PSMA-targeted radioligand therapy for prostate cancer diseases.
-
公开(公告)号：US20210121585A1
公开(公告)日：2021-04-29
申请号：US16663387
申请日：2019-10-25
申请人： MING-HSIN LI , Sheng-Nan Lo , Shih-Wei Lo , Shih-Ying Lee , Su-Jung Chen , Shih-Min Wang , Ming-Wei Chen , Wei-Lin Lo
发明人： MING-HSIN LI , Sheng-Nan Lo , Shih-Wei Lo , Shih-Ying Lee , Su-Jung Chen , Shih-Min Wang , Ming-Wei Chen , Wei-Lin Lo
IPC分类号： A61K51/08
摘要： The invention features a novel precursor provided for radioisotope labeling with ligands for specific binding of prostate-specific membrane antigen (PSMA) for prostate cancer diagnosis and treatment, and the pharmacophore of a PSMA inhibitor composed of three molecules of glutamic acid, urea and lysine is provided with three variable linkers based on pharmacological activity of the PSMA inhibitor for labeling with radioactive nucleus Ga-67, Ga-68, In-111, Lu-177, Cu-64, or Y-90 through a chelating agent for imaging analysis of human tumor models of prostate cancer and serving as a PSMA-targeted radioligand therapy for prostate cancer diseases.
-
5.发明申请公开(公告)号：US20200078478A1
公开(公告)日：2020-03-12
申请号：US16125787
申请日：2018-09-10
申请人： Ming-Hsin Li , Ming-Wei Chen , Shin-Min Wang , Shih-Wei Lo , Chun-Fang Feng , Cheng-Hui Chuang , Sheng-Nan Lo
发明人： Ming-Hsin Li , Ming-Wei Chen , Shin-Min Wang , Shih-Wei Lo , Chun-Fang Feng , Cheng-Hui Chuang , Sheng-Nan Lo
IPC分类号： A61K51/04
摘要： A PSMA targeting peptide derivative for radiotherapy, which is a structural molecule developed for diagnosis or treatment of prostate cancer, as prostate-specific membrane antigen (PSMA) is a protein present on the surface of healthy prostate cells, which is often at a high level of expression on the surface of prostate cancer cells, and the molecular composition of PSMA inhibitor is mainly composed of glutamic acid, urea and lysine, in addition to the linker of the present invention, PSMA inhibitor can be combined with a chelating agent and truncated Evans Blue, which can be labeled with radionuclides Ga-67, Ga-68, In-111, Lu-177, Cu-64 or Y-90, used for image analysis and analysis of human prostate cancer tumor pattern as a new PSMA targeting peptide receptor radionuclide therapy (PRRT), and which has a longer half-life in vivo and is featured by specific binding of PSMA for radiotherapy diagnosis or treatment.
-
-
-
-
搜索结果
5 条记录 (耗时 0.038 秒)
